Table 1.
Fold induction for the indicated metabolites measured upon in vivo treatment with AAE.
| PUFA | Metabolite | Fold Change 1 | PUFA | Metabolite | Fold Change 1 |
|---|---|---|---|---|---|
| ARA | DHA | ||||
| ARA 20:4ω-6 * | 1.0 ± 0.1 | DHA 22:6ω-3 * | 0.9 ± 0.2 | ||
| Tetranor 12-HETE | 3.4 ± 0.2 | 17-HDoHE | 1.0 ± 0.1 | ||
| 14,15-DiHETrE | 3.5 ± 0.1 | 13-HDoHE | 1.1 ± 0.1 | ||
| 2,3-Dinor-6-keto-PGF1α | 1.6 ± 0.2 | 19,20-DiHDPA | 1.3 ± 0.1 | ||
| 15-Keto-13,14-dihydroPGA2 | 1.0 ± 0.1 | ||||
| PGF2α | 1.6 ± 0.1 | α-LA | |||
| 13,14-dihydro-PGF2α | 2.3 ± 0.2 | α-LA 18:3ω-3 * | 1.1 ± 0.1 | ||
| 15-deoxy-Δ12,14-PGJ2 | 1.1 ± 0.1 | LA | |||
| LA 18:2ω-6 * | 0.9 ± 0.1 | ||||
| EPA | 9,10-DHOME | specific for AAE | |||
| EPA 20:5ω-3 * | 0.9 ± 0.1 | 13-HpODE | 2.3 ± 0.1 | ||
| 5-HEPE | 1.0 ± 0.1 | 9,12,13-TriHOME | 1.3 ± 0.1 |
1 (n = 15. Shown is mean ± s.e.m.); * indicates unprocessed PUFA. The abbreviations of PUFA metabolites as well as their full IUPAC names are shown in Table S1.